Harvard Bioscience (HBIO) Revenue (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Revenue data on file, last reported at $20.8 million in Q1 2026.

• Quarterly Revenue fell 4.68% year-over-year to $20.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $85.5 million (down 6.42% YoY) and the FY2025 annual result came in at $86.6 million, down 8.06% from the prior year.
• Revenue retreated to $20.8 million in Q1 2026 per HBIO's latest filing, from $23.7 million in the prior quarter.
• Across five years, Revenue topped out at $30.0 million in Q1 2023 and bottomed at $20.4 million in Q2 2025.
• The 5-year median for Revenue is $24.6 million (2024), against an average of $25.1 million.
• The widest annual swing landed in 2022, when Revenue climbed 6.63%; it then decreased 19.69% in 2024.
• Tracing HBIO's Revenue over 5 years: stood at $28.4 million in 2022, then slipped by 0.96% to $28.2 million in 2023, then fell by 12.78% to $24.6 million in 2024, then fell by 3.34% to $23.7 million in 2025, then decreased by 12.56% to $20.8 million in 2026.
• Per Business Quant, the three latest HBIO Revenue figures stand at $20.8 million (Q1 2026), $23.7 million (Q4 2025), and $20.6 million (Q3 2025).

Peer Comparison